Upcoming Webinar:Join the webinar on ' Unique ways of participating in agri commodity derivatives' on June 18, 5pm. Register Now!

Mangalam Drugs & Organics – valuation comfort for this small cap

For a company on a turnaround journey where the return ratios have started looking up meaningfully, the undemanding valuation at 9X FY19 projected earnings should be looked at seriously by investors

December 01, 2017 / 07:40 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Mangalam Drugs and Organics is a small cap pharmaceutical company (market cap: Rs 253 crore) that is on a gradual path of turnaround. The company has created a niche for itself in antimalarial API (active pharmaceutical ingredients) and has become one of the largest manufacturers in anti-malarial APIs (active pharmaceutical ingredients) in India and is now getting into API for antiretroviral drugs (anti-AIDS). While a predominantly one-product company, the approvals from large global buyers, entry into new segment and an undemanding valuations beckons attention.

The difficult past

While Mangalam was a loss-making entity in FY14, the business turnaround has been visible in the past three years and the result of the quarter gone by was impressive.

madhu-1

While the margin improvement stood out in Q2 FY18, it has to be seen in the context of the absence of excise duty in the cost head.

Close

The products

The company principally manufactures anti-malarial API like Arthemether, Lumefrantine, Artesunate, Amodiaquine Hydrochloride, Dihydroartemisinin, Piperaquine phosphate, Chloroquine Phosphate, Hydroxychloroquine Sulphate and Pyronaridine tetraphosphate. It has also forayed into anti retroviral API’s and has received approval and is manufacturing Tenofovir Disoproxyl Fumarate.

What are its niches?

Globally accredited facility - The company manufactures APIs and intermediates from its WHO-GMP certified plants in Vapi. It has also signed a pact with the prestigious Bill Clinton Foundation under their Fight Malaria Program for supply of anti-malarial bulk drugs worldwide.

Capacity in place - The company has expanded capacity by around 900 tonnes/year and demand for its products supported by World Health Organisation’s (WHO) thrust on malaria and HIV/AIDS treatment should translate into higher revenue in the coming years despite competitive intensity in the segments.

Product diversification strategy -The company has been consistently filing DMFs (drug master file). After establishing itself in malaria, the company aims to become an established player in Anti-AIDS APIs too and finally eye that lucrative WHO Anti-AIDS funding and that should certainly give a major fillip to future earnings.

Financials showing traction - In the past three years, while the revenue has grown at a CAGR (compounded annual growth rate) of 37 percent, operating profit has shown a growth of 70 percent and the company has turned itself from a loss making entity to a path of healthy profitability.

While there is still some leverage on the books, the debt-to-equity ratio has fallen from 2.4x to 0.7x. It is important to note that the company has improved its interest coverage ratio from 0.98x couple of years back to close to 4x now. The double-digit EBIDTA margin should impart further health to the balance sheet.

Raw material price volatility – while the company’s EBITDA margins are impacted to the extent of price volatility in artemisinin - the core raw material for its products, it can pass on raw material price fluctuations to its clients, although the same is effected with a time lag.

Anti-malarial APIs account for close to 90 percent of the company’s revenue and the company has high customer concentration with top two clients Ajanta Pharma and Cipla contributing significantly to the total revenue. The company is exposed to the risk arising from a drop in anti-malarial API demand or a drop in demand from its clients. However, a successful diversification to other therapeutic categories should mitigate the risk.

Undemanding valuation – For a company on a turnaround journey where the return ratios have started looking up meaningfully, the undemanding valuation at 9X FY19 projected earnings should be looked at seriously by investors with a slightly higher appetite for risk.

Madhu-2
Madhuchanda Dey
first published: Dec 1, 2017 07:40 pm

stay updated

Get Daily News on your Browser
Sections